AnaptysBio, Inc. ANAB Biopharma Company — Net Income Loss
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s biopharma company — net income loss.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s biopharma company — net income loss?
- AnaptysBio, Inc. (ANAB) reported biopharma company — net income loss of -$50.48M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — net income loss changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — net income loss decreased by 7.0% year-over-year, from -$47.2M to -$50.48M.
- What does biopharma company — net income loss mean?
- This metric represents the bottom-line financial result for the biopharma business segment, calculated as total revenues minus all operating and non-operating expenses. It serves as the primary indicator of the segment's overall profitability or burn rate. For early-stage biotechnology firms, this figure is typically negative as capital is prioritized for clinical development.